Literature DB >> 3502675

Magnetic resonance imaging (MRI), cranial computerized tomography (CCT), evoked potentials and cerebrospinal fluid (CSF) analysis in five patients with funicular myelosis.

J Haan1, M Haupts, D Uhlenbrock.   

Abstract

Five Patients with vitamin B12 deficiency were examined by means of MRI, CCT, VEP, BAEP, EEG, and CSF. In 3 patients medianus-SEP and EMG/ENG were recorded as well. Partly, findings of MRI, CCT, VEP, BAEP, SEP, and CSF were similar to those in multiple sclerosis. This is not very surprising considering that the central nervous system lesions in vitamin B12 deficiency consist of disseminated demyelination. Because of this all these investigative techniques must be considered non-specific. Appraisal of findings is only possible in connection with the case history, clinical findings, and supplementary diagnostic measurements.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3502675     DOI: 10.1007/BF01782049

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  3 in total

1.  Cranial magnetic resonance imaging in multiple sclerosis--indicated only in exceptional cases?

Authors:  M Haupts; J Haan
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

2.  [Central pontine myelinolysis in alcoholism. Clinical aspects, neurophysiology, computerized tomography and nuclear magnetic resonance tomography in a patient who survived].

Authors:  J Haan; A Deppe
Journal:  Nervenarzt       Date:  1986-10       Impact factor: 1.214

3.  Nuclear magnetic resonance imaging of the brain in multiple sclerosis.

Authors:  I R Young; A S Hall; C A Pallis; N J Legg; G M Bydder; R E Steiner
Journal:  Lancet       Date:  1981-11-14       Impact factor: 79.321

  3 in total
  1 in total

1.  Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute transverse myelitis.

Authors:  Katharina Wolf; Thomas Schmitt-Mechelke; Spyridon Kollias; Armin Curt
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.